# EDGAR Filing Document

**Accession Number:** 0001384101
**File Stem:** 0001020741-25-000004
**Filing Date:** 2025-11
**Character Count:** 8842
**Document Hash:** 6a77044b0acfae12c964980280f481e2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001020741-25-000004.hdr.sgml**: 20251107

**ACCESSION NUMBER**: 0001020741-25-000004

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251105

**FILED AS OF DATE**: 20251107

**DATE AS OF CHANGE**: 20251107

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** JONES EVAN/ FA
- **CENTRAL INDEX KEY:** 0001020741

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36156
- **FILM NUMBER:** 251462746

**BUSINESS ADDRESS:**
- **STREET 1:** 9000 VIRGINIA MANOR ROAD
- **STREET 2:** SUITE 206
- **CITY:** BELTSVILLE
- **STATE:** MD
- **ZIP:** 20705
- **BUSINESS PHONE:** (650) 243-6300

**MAIL ADDRESS:**
- **STREET 1:** C/O VERACYTE, INC.
- **STREET 2:** 6000 SHORELINE COURT, SUITE 300
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** VERACYTE, INC.
- **CENTRAL INDEX KEY:** 0001384101
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 205455398
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 6000 SHORELINE COURT, SUITE 300
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** (650) 243-6300

**MAIL ADDRESS:**
- **STREET 1:** 6000 SHORELINE COURT, SUITE 300
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CALDEROME INC
- **DATE OF NAME CHANGE:** 20061219

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>JONES EVAN/ FA<br><sub>(Last) (First) (Middle)</sub><br>6000 SHORELINE COURT<br>SUITE 300<br><sub>(Street)</sub><br>SOUTH SAN FRANCISCO, CA 94080<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-11-05 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>VERACYTE, INC. [ VCYT ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-11-05 |  | M<sup>(1)</sup> |  | 10000 | A | $5.28 | 53664 | D |  |
| Common Stock | 2025-11-05 |  | M<sup>(1)</sup> |  | 10000 | A | $7.94 | 63664 | D |  |
| Common Stock | 2025-11-05 |  | M<sup>(1)</sup> |  | 10000 | A | $7.60 | 73664 | D |  |
| Common Stock | 2025-11-05 |  | S<sup>(1)</sup> |  | 408 | D | 41.7431<sup>(2)</sup> | 73256 | D |  |
| Common Stock | 2025-11-05 |  | S<sup>(1)</sup> |  | 1126 | D | 43.0329<sup>(3)</sup> | 72130 | D |  |
| Common Stock | 2025-11-05 |  | S<sup>(1)</sup> |  | 10837 | D | 43.8038<sup>(4)</sup> | 61293 | D |  |
| Common Stock | 2025-11-05 |  | S<sup>(1)</sup> |  | 5872 | D | 45.0682<sup>(5)</sup> | 55421 | D |  |
| Common Stock | 2025-11-05 |  | S<sup>(1)</sup> |  | 24296 | D | 45.7273<sup>(6)</sup> | 31125 | D |  |
| Common Stock | 2025-11-05 |  | S<sup>(1)</sup> |  | 657 | D | 46.3756<sup>(7)</sup> | 30468 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (right to buy) | $5.28 | 2025-11-05 |  | M<sup>(1)</sup> |  |  | 10000 | <sup>(8)</sup> | 2026-06-20 | Common Stock | 10000 | $0 | 0 | D |  |
| Stock Option (right to buy) | $7.94 | 2025-11-05 |  | M<sup>(1)</sup> |  |  | 10000 | <sup>(8)</sup> | 2027-06-07 | Common Stock | 10000 | $0 | 0 | D |  |
| Stock Option (right to buy) | $7.60 | 2025-11-05 |  | M<sup>(1)</sup> |  |  | 10000 | <sup>(8)</sup> | 2028-06-07 | Common Stock | 10000 | $0 | 0 | D |  |

---

### Footnotes:

(1) The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 9, 2024.

(2) Represents weighted average sales price.  Sale prices for the transactions range from $41.10 to $41.97.  Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

(3) Represents weighted average sales price.  Sale prices for the transactions range from $42.285 to $43.20.  Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

(4) Represents weighted average sales price.  Sale prices for the transactions range from $43.29 to $44.29.  Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

(5) Represents weighted average sales price.  Sale prices for the transactions range from $44.335 to $45.335.  Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

(6) Represents weighted average sales price.  Sale prices for the transactions range from $45.34 to $44.33.  Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

(7) Represents weighted average sales price.  Sale prices for the transactions range from $46.35 to $46.40.  Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

(8) The option is fully vested.

**Signature:** /s/ Jonathan Wygant, as attorney-in-fact  
**Date:** 2025-11-07

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**